Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02805075 · ClinicalTrials.gov registry record · Phase 1

Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

A Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Hematologic Malignancy, sponsored by Stanford University.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT02805075 is a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Hematologic Malignancy that has completed, run by Stanford University. The registered enrollment target is 15 participants, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02805075, a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Hematologic Malignancy, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in treating patients with blood cancer who are undergoing donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Nutritional supplements such as fructooligosaccharides may reduce the incidence of graft-versus-host disease in patients with blood cancer undergoing donor stem cell transplant.

Conditions Studied

Hematopoietic and Lymphoid Cell Neoplasm Recurrent Hematologic Malignancy

Interventions

  • OTHER Laboratory Biomarker Analysis
  • OTHER Fructooligosaccharide

Study Locations (1)

California

  • Stanford University, School of Medicine - Palo Alto

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2016-06
Est. Completion 2017-11-17
Phase Phase 1

Sponsor

Stanford University

1,744 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02805075

The ClinicalTrials.gov registry entry for NCT02805075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (98% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02805075 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02805075 about?

NCT02805075 is a clinical study titled "Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant". This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in treating patients with blood cancer who are undergoing donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-vers...

What is the current status of trial NCT02805075?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-06. Estimated completion is 2017-11-17.

What conditions does trial NCT02805075 study?

This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Hematologic Malignancy.

What interventions are being tested in trial NCT02805075?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Fructooligosaccharide (OTHER).

Who is sponsoring clinical trial NCT02805075?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02805075 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hematopoietic and Lymphoid Cell Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hematopoietic and Lymphoid Cell Neoplasm

All registered trials for this condition

Recurrent Hematologic Malignancy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.